Skip to Content

Tiagabine Pregnancy and Breastfeeding Warnings

Tiagabine is also known as: Gabitril

Tiagabine Pregnancy Warnings

High dose reproductive studies in animals have demonstrated teratogenic effects (craniofacial, appendicular, and visceral malformations), maternal toxicity (transient weight loss or reduced maternal weight gain during gestation), as well as adverse fetal outcome when the drug is administered during late gestation and throughout parturition (increase in stillbirths and decrease in postnatal offspring viability). No adverse fetal or maternal effects were observed with doses equivalent to three times the maximum recommended human dose on a mg/m2 basis. There are no controlled data in human pregnancy. Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk. AU TGA pregnancy category: B3 US FDA pregnancy category: C Comments: -The risk of having an abnormal child as a result of antiepileptic medication is far outweighed by the dangers to the mother and fetus of uncontrolled epilepsy. -Women on antiepileptic drugs (AEDs) should receive prepregnancy counseling about the risk of potential fetal abnormalities. -AEDs should be continued during pregnancy and monotherapy should be used if possible at the lowest effective dose because risk of abnormality is greater in women taking combined medication. -Folic acid supplementation (5 mg) should be started 4 weeks prior to and continue for 12 weeks after conception. -Specialist prenatal diagnosis including detailed mid-trimester ultrasound should be offered.

See references

Tiagabine Breastfeeding Warnings

Monitor the infant for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of anticonvulsant or psychotropic drugs. Because there is very limited published experience with this drug during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.

Benefit should outweigh risk. Excreted into human milk: Unknown Excreted into animal milk: Yes

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Tiagabine Hydrochloride (tiaGABine (tiagabine))." Teva Pharmaceuticals USA, North Wales, PA.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  2. "Product Information. Tiagabine Hydrochloride (tiaGABine (tiagabine))." Teva Pharmaceuticals USA, North Wales, PA.
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide